
Paul L. Swiecicki, MD, of the University of Michigan Rogel Cancer Center, compares subcutaneous amivantamab with 2 other EGFR-directed bispecific antibodies advancing toward phase 3 readouts in head and neck squamous cell carcinoma (HNSCC): petosemtamab and ficerafusp alfa.














